Literature DB >> 11572934

Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism.

N Lila1, N Rouas-Freiss, J Dausset, A Carpentier, E D Carosella.   

Abstract

We recently reported that the nonclassical HLA class I molecule HLA-G was expressed in the endomyocardial biopsies and sera of 16% of heart transplant patients studied. The aim of the present report is to identify cells that may be responsible for HLA-G protein expression during the allogeneic reaction. Carrying out mixed lymphocyte cultures in which the responder cell population was depleted either in CD4(+) or CD8(+) T cells, we found that soluble HLA-G5 protein but not the membrane-bound HLA-G isoform was secreted by allo-specific CD4(+) T cells from the responder population, which suppressed the allogeneic proliferative T cell response. This inhibition may be reversed by adding the anti-HLA-G 87G antibody to a mixed lymphocyte culture. That may indicate a previously uncharacterized regulatory mechanism of CD4(+) T cell proliferative response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572934      PMCID: PMC59783          DOI: 10.1073/pnas.201407398

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Modulation of HLA-G expression in human thymic and amniotic epithelial cells.

Authors:  S Lefebvre; F Adrian; P Moreau; L Gourand; J Dausset; S Berrih-Aknin; E D Carosella; P Paul
Journal:  Hum Immunol       Date:  2000-11       Impact factor: 2.850

2.  Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8.

Authors:  S Fournel; M Aguerre-Girr; X Huc; F Lenfant; A Alam; A Toubert; A Bensussan; P Le Bouteiller
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

3.  Implication of HLA-G molecule in heart-graft acceptance.

Authors:  N Lila; A Carpentier; C Amrein; I Khalil-Daher; J Dausset; E D Carosella
Journal:  Lancet       Date:  2000-06-17       Impact factor: 79.321

4.  HLA-G suppresses proliferation of CD4(+) T-lymphocytes.

Authors:  D R Bainbridge; S A Ellis; I L Sargent
Journal:  J Reprod Immunol       Date:  2000-08       Impact factor: 4.054

5.  Regulation of the human allogenic proliferative response in vitro. II. Production of soluble suppressor factors by suppressor T cells and evidence in favor of "acceptor" cells for suppression among unprimed lymphocytes.

Authors:  M Sasportes; E Carosella; A Bensussan; C Mihaesco; J Dausset
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

6.  A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta.

Authors:  S Lefebvre; S Berrih-Aknin; F Adrian; P Moreau; S Poea; L Gourand; J Dausset; E D Carosella; P Paul
Journal:  J Biol Chem       Date:  2000-11-21       Impact factor: 5.157

7.  HLA-G has a concentration-dependent effect on the generation of an allo-CTL response.

Authors:  K Kapasi; S E Albert; S Yie; N Zavazava; C L Librach
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

8.  HLA-G class I gene expression in normal and malignant hematopoietic cells.

Authors:  L Amiot; M Onno; B Drénou; C Monvoisin; R Fauchet
Journal:  Hum Immunol       Date:  1998-08       Impact factor: 2.850

9.  A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4.

Authors:  T Fujii; A Ishitani; D E Geraghty
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

10.  A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.

Authors:  M Colonna; F Navarro; T Bellón; M Llano; P García; J Samaridis; L Angman; M Cella; M López-Botet
Journal:  J Exp Med       Date:  1997-12-01       Impact factor: 14.307

View more
  79 in total

1.  HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels.

Authors:  Thomas Vauvert F Hviid; Sine Hylenius; Christina Rørbye; Lone G Nielsen
Journal:  Immunogenetics       Date:  2003-04-24       Impact factor: 2.846

2.  Dynamic expression of Qa-2 during acute graft rejection.

Authors:  Nan Lu; Chuanxin Wang; Xiaojing Yang; Shengmei Zhao; Xiangdong Li; Xiaoli Li; Hong Jiang; Jinbo Feng; Yi Zhang; Xiong Zou
Journal:  Mol Med       Date:  2010-11-12       Impact factor: 6.354

Review 3.  HLA-G: a look back, a look forward.

Authors:  Edgardo D Carosella; Joel LeMaoult
Journal:  Cell Mol Life Sci       Date:  2010-11-19       Impact factor: 9.261

Review 4.  Emerging topics and new perspectives on HLA-G.

Authors:  Enrico Fainardi; Massimiliano Castellazzi; Marina Stignani; Fabio Morandi; Gwenaëlle Sana; Rafael Gonzalez; Vito Pistoia; Olavio Roberto Baricordi; Etienne Sokal; Josè Peña
Journal:  Cell Mol Life Sci       Date:  2010-11-16       Impact factor: 9.261

5.  On the definition of a criterion of immunogenicity.

Authors:  Thomas Pradeu; Edgardo D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

6.  Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis.

Authors:  L Donaghy; F Gros; L Amiot; C Mary; A Maillard; C Guiguen; J-P Gangneux
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 7.  Nanoparticles targeting HLA-G for gene therapy in cancer.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2011-04-17       Impact factor: 3.064

8.  HLA-G is found in lipid rafts and can act as a signaling molecule.

Authors:  Martina Comiskey; Kenneth E Domino; Carol M Warner
Journal:  Hum Immunol       Date:  2006-11-03       Impact factor: 2.850

Review 9.  New aspects in celiac disease.

Authors:  M I Torres; M A López Casado; A Ríos
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

10.  Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Christian Spurny; Silke Jamitzky; Sonja Schelhaas; Andreas H Jacobs; Constanze Wiek; Katharina Roellecke; Helmut Hanenberg; Wolfgang Hartmann; Heinz Wiendl; Susann Pankratz; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Claudia Rossig
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.